{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T22:15:52Z","timestamp":1768515352075,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019650","name":"Vir Biotechnology Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["218263"],"award-info":[{"award-number":["218263"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["219589"],"award-info":[{"award-number":["219589"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clinthera.2025.01.003","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T08:52:52Z","timestamp":1738831972000},"page":"284-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Effectiveness of Sotrovimab in Ambulatory Patients With COVID-19: A Retrospective Cohort Study Using a Large Administrative Claims Database in the United States"],"prefix":"10.1016","volume":"47","author":[{"given":"Christopher F.","family":"Bell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasneem","family":"Lokhandwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Drysdale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily J.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.01.003_bib0001","unstructured":"World Health Organization. Coronavirus disease (COVID-19) pandemic. Available at: https:\/\/www.who.int\/europe\/emergencies\/situations\/covid-19. Accessed November 20, 2023."},{"key":"10.1016\/j.clinthera.2025.01.003_bib0002","unstructured":"World Health Organization. WHO coronavirus (COVID-19) dashboard. Available at: https:\/\/covid19.who.int\/. Accessed November 20, 2023."},{"key":"10.1016\/j.clinthera.2025.01.003_bib0003","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) | Drugs. Available at: https:\/\/www.fda.gov\/drugs\/emergency-preparedness-drugs\/coronavirus-covid-19-drugs. Accessed November 20, 2023."},{"key":"10.1016\/j.clinthera.2025.01.003_bib0004","unstructured":"National Institutes of Health. Anti-SARS-CoV-2 monoclonal antibodies. Available at: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antivirals-including-antibody-products\/anti-sars-cov-2-monoclonal-antibodies\/. Accessed November 20, 2023."},{"key":"10.1016\/j.clinthera.2025.01.003_bib0005","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jama.2022.2832","article-title":"Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial","volume":"327","author":"Gupta","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0006","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus etesevimab in mild or moderate Covid-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0007","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV antibody combination to prevent Covid-19","volume":"385","author":"O'Brien","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0008","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with Covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0009","unstructured":"American Hospital Association. HHS reinstates original distribution method for COVID-19 monoclonal antibody therapies. 2021. Available at: https:\/\/www.aha.org\/special-bulletin\/2021-09-17-hhs-reinstates-original-distribution-method-covid-19-monoclonal. Accessed November 5, 2024."},{"key":"10.1016\/j.clinthera.2025.01.003_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0011","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal Fc receptor function improves protection against primate SHIV infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0012","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0013","article-title":"The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2","author":"Cathcart","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0014","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0015","unstructured":"Centers for Disease Control and Prevention. COVID data tracker. Available at: https:\/\/covid.cdc.gov\/covid-data-tracker\/#variant-proportions. Accessed December 6, 2023."},{"key":"10.1016\/j.clinthera.2025.01.003_bib0016","doi-asserted-by":"crossref","first-page":"e1003","DOI":"10.1016\/S2214-109X(20)30264-3","article-title":"Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study","volume":"8","author":"Clark","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0017","doi-asserted-by":"crossref","first-page":"e05684","DOI":"10.1016\/j.heliyon.2020.e05684","article-title":"Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: a meta-analysis with 55 studies and 10014 cases","volume":"6","author":"Barek","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0018","first-page":"E329","article-title":"Age-related risk factors and severity of SARS-CoV-2 infection: a systematic review and meta-analysis","volume":"62","author":"Rahman","year":"2021","journal-title":"J Prev Med Hyg"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0019","doi-asserted-by":"crossref","first-page":"o1431","DOI":"10.1136\/bmj.o1431","article-title":"Comorbidities and covid-19","volume":"377","author":"Adab","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0020","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.5888\/pcd18.210123","article-title":"Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020-March 2021","volume":"18","author":"Kompaniyets","year":"2021","journal-title":"Prev Chronic Dis"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0021","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1126\/science.adc9127","article-title":"Imprinted antibody responses against SARS-CoV-2 Omicron sublineages","volume":"378","author":"Park","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0022","first-page":"e12","article-title":"Antiviral agents against Omicron subvariant BA.4.6 in vitro","volume":"388","author":"Walker","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0024","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1038\/s41467-022-31615-7","article-title":"Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains","volume":"13","author":"Case","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-022-04856-1","article-title":"Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2","volume":"607","author":"Uraki","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0026","article-title":"Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants","author":"Addetia","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0027","first-page":"1","article-title":"Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review","volume":"552","author":"Drysdale","year":"2023","journal-title":"Infection"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0028","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40121-022-00755-0","article-title":"Real-world effectiveness of sotrovimab for the early treatment of COVID-19 during SARS-CoV-2 Delta and Omicron waves in the USA","volume":"12","author":"Cheng","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0029","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/infdis\/jiac206","article-title":"Real-world evidence of the neutralizing monoclonal antibody sotrovimab for preventing hospitalization and mortality in COVID-19 outpatients","volume":"226","author":"Aggarwal","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0030","article-title":"Effectiveness of sotrovimab and molnupiravir in community settings in England across the Omicron BA.1 and BA.2 sublineages: emulated target trials using the OpenSAFELY platform","author":"Tazare","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0031","article-title":"Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England","author":"Patel","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0032","article-title":"Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England","author":"Patel","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0033","article-title":"Comparative effectiveness of Paxlovid versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised patients: observational cohort study using the OpenSAFELY platform","author":"Zheng","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0034","article-title":"Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform","volume":"379","author":"Zheng","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0035","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/cid\/ciac186","article-title":"Real-world incidence of breakthrough Coronavirus Disease 2019 hospitalization after vaccination vs natural infection in a large, local, empaneled primary care population using time-to-event analysis","volume":"75","author":"Pollock","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0036","doi-asserted-by":"crossref","first-page":"ofad605","DOI":"10.1093\/ofid\/ofad605","article-title":"Effectiveness of sotrovimab in preventing COVID-19-related hospitalizations or death among US veterans during Omicron BA.1","volume":"10","author":"Young-Xu","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0037","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40261-024-01344-4","article-title":"Real-world effectiveness of sotrovimab for the early treatment off COVID-19: evidence from the US National COVIID Cohort Collaborative (N3C)","volume":"44","author":"Bell","year":"2024","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304822","article-title":"Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: a cohort study from the Mayo Clinic electronic health records","volume":"19","author":"Bell","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279326","article-title":"Lack of effectiveness of bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era","volume":"18","author":"Sridhara","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijid.2023.04.396","article-title":"Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4\/BA.5","volume":"132","author":"Molina","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0041","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(23)00011-7","article-title":"Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of Omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study","volume":"23","author":"Aggarwal","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-064953","article-title":"Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting: a retrospective cohort study using a large claims database","volume":"12","author":"Hussein","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0043","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s40121-022-00691-z","article-title":"Effectiveness of subcutaneous casirivimab and imdevimab in ambulatory patients with COVID-19","volume":"11","author":"Jalbert","year":"2022","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0044","doi-asserted-by":"crossref","first-page":"e12550","DOI":"10.1002\/emp2.12550","article-title":"Emergency department implementation of monoclonal antibody infusion for the treatment of coronavirus disease 2019: a template for rapid deployment","volume":"2","author":"Woltemate","year":"2021","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"10.1016\/j.clinthera.2025.01.003_bib0045","unstructured":"Cooke M., Madoff L.; The Commonwealth of Massachusetts. Updates for patients receiving COVID-19 monoclonal antibodies therapeutic infusions, bamlanivimab\/etesevimab and REGEN-COV (Casirivimab\/Imdevimab). Available at: https:\/\/www.mass.gov\/doc\/guidance-for-allocation-of-covid-19-monoclonal-antibody-therapeutics-in-non-hospital-settings\/download. Accessed November 5, 2024."},{"key":"10.1016\/j.clinthera.2025.01.003_bib0046","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.chest.2021.08.003","article-title":"A novel approach to equitable distribution of scarce therapeutics: institutional experience implementing a reserve system for allocation of COVID-19 monoclonal antibodies","volume":"160","author":"Rubin","year":"2021","journal-title":"Chest"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T09:22:28Z","timestamp":1741684948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825000049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0149291825000049"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.01.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Effectiveness of Sotrovimab in Ambulatory Patients With COVID-19: A Retrospective Cohort Study Using a Large Administrative Claims Database in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}